[Telematic multicenter study of Pragmarel 100 mg (trazodone)].
Trazodone is a molecule which is already well known throughout the world for its antidepressant properties and its good global safety. We have conducted a large national study in outpatients. By means of a computerized communication network (233 psychiatrists equipped with Minitel), almost 2,000 depressed patients have been followed over a four week period of treatment with Pragmarel 100 mg, in less than three months. Computerized DSM III diagnostic criteria were used to define two sub-groups of patients. The results confirm the therapeutic indications of trazodone in various forms of depression, major affective disorders (689 cases) and other affective disorders (1,257 cases). 82% good and very good results were obtained in the overall population of patients, with a decrease by more than 50% in the initial score on the MADRS scale in 65% of cases. The low incidence of side effects and the excellent acceptability of treatment also confirm the date reported in the literature.